InvestorsHub Logo
Followers 15
Posts 240
Boards Moderated 0
Alias Born 01/31/2018

Re: None

Wednesday, 04/29/2020 4:08:47 PM

Wednesday, April 29, 2020 4:08:47 PM

Post# of 232952
The Gilead news may not turn out all that bad for CytoDyn.

Gilead set the bar for approval - survival, recovery, viral load, side effects. The bar has also been set that the FDA will act earlier than protocol.

When published leronlimab data improves upon Remdesivir in every category, it will be awfully hard to argue it doesn't deserve the same treatment.

Again, IMHO, Fauci was looking for anything with plausible data that will get people off hydroxychloroquine.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News